FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.	C.	20549
----------------	----	-------

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL								
OMB Number: 3235-028								
Estimated average burden								
hours por response:	0.5							

	Check this box if no longer subject to							
	Section 16. Form 4 or Form 5 obligations may continue. See							
\cup	obligations may continue. See							
	Instruction 1(b)							

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Name and Address of Reporting Person* Taglietti Marco					2. Issuer Name and Ticker or Trading Symbol Aquestive Therapeutics, Inc. [AQST]							elationship o eck all applic Director	able)	g Pers	10% Ow	mer	
(Last)	`	rst) THERAPEUTIC	(Middle) S, INC.		Date o		Trans	saction (Month	/Day/Year)		Officer below)	ficer (give title low)		Other (s below)	pecify		
30 TECHNOLOGY DRIVE				4.	4. If Amendment, Date of Original Filed (Month/Day/Year)							6. Individual or Joint/Group Filing (Check Applicable Line)					
(Street) WARRE	N N.	J	07059							2	Form filed by One Reporting Person Form filed by More than One Report Person						
(City)	(Si	tate)	(Zip)														
	Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned																
Date			Date	ansaction e nth/Day/Year)		2A. Deemed Execution Date, if any (Month/Day/Year)		Code (Inst				5. Amour Securitie Beneficia Owned F	s ally ollowing	Form: Direct		7. Nature of Indirect Beneficial Ownership (Instr. 4)	
							Code V	Amount	(A) or (D)	Price	Transact (Instr. 3 a	tion(s)					
	Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transa Code (8)				e	7. Title and of Securit Underlying Derivative (Instr. 3 and	ies g Security	8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)		
				Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares						
Stock Option (Right to Purchase)	\$4.04	06/15/2021		A		20,000		06/15/2022 ⁽¹⁾	06/15/2031	Common Stock	20,000	\$0	20,000	0	D		

Explanation of Responses:

1. The shares underlying the options vest as follows: 100% of the underlying shares vest June 15, 2022, subject to Dr. Taglietti's continuous service with the Issuer from the grant date through the applicable vesting date.

Remarks:

/s/ Lori J. Braender, as Attorney-In-Fact

06/17/2021

** Signature of Reporting Person

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.